The drugs show pharma at its best and its worst: drugs such as Vertex's Orkambi and Novartis ... EMA in September), both cut LDL cholesterol by more than 60% in hard-to-treat patients, but ...

Cahill Gordon & Reindel LLP announced today that Andrew Cochran, Michael Dvorak, Michael Makhotin, and Nikolas Rodriguez have ...

ClearBridge Growth Strategy highlighted stocks like Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), in the third quarter 2024 investor letter. Vertex Pharmaceuticals Incorporated (NASDAQ ...

Zai Lab (ZLAB) and Vertex Pharmaceuticals (VRTX) announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept in mainland China ...

Ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) were provided by 23 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a concise ...

Vertex Pharmaceuticals Incorporated (VRTX), headquartered in Boston, Massachusetts, is a global leader in biotechnology and precision medicine. With a market cap of $106.1 billion, Vertex ...

In a report released today, Mohit Bansal from Wells Fargo assigned a Buy rating to Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $460.00. The company’s shares closed ...

Orna Therapeutics, through its wholly owned subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with Vertex Pharmaceuticals (VRTX) to utilize Orna’s novel ...

Vertex Pharmaceuticals stock opened at $397.27 on Thursday. The firm has a market cap of $102.31 billion, a price-to-earnings ratio of -199.63 and a beta of 0.36. Vertex Pharmaceuticals has a 52 ...

Vertex Pharmaceuticals’ Death Cross signals a bearish trend as shares fall below all critical moving averages. Clinical trial disappointments and technical sell signals pressure VRTX ...

StockNews.com cut shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 21st. Finally, Canaccord Genuity Group boosted their ...

Vertex Pharmaceuticals Inc. will work with a Watertown biotech on new gene-editing therapies for people with sickle cell disease and transfusion-dependent beta thalassemia. A Watertown biotech is ...